Try our mobile app

Oncocyte Reports Third Quarter 2023 Financial Results

Published: 2023-11-09 12:00:00 ET
<<<  go to OCX company page

-Launching First Products in 1H 2024-

-Conference Call on Thursday, November 9, 2023 at 5:00 a.m. PT / 8:00 a.m. ET-

IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the third quarter of 2023, ended September 30, 2023.

Third Quarter and Recent Highlights

  • VitaGraft™ Kidney, the Company’s kidney transplant diagnostic test, received a positive coverage decision from CMS coverage; commercial revenue is expected beginning in 1H 2024.
  • Significant new clinical data was presented at the European Society of Organ Transplant Conference demonstrating the VitaGraft assay detects antibody-mediated transplant rejection 10 months sooner than commonly used monitoring protocols (p